You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,808,540

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,808,540

Title:	Contrast agent for nuclear magnetic resonance imaging comprising melanin nanoparticles stably dispersed in water
Abstract:	The present invention relates to a contrast agent for nuclear magnetic resonance imaging, and more particularly, to a contrast agent for nuclear magnetic resonance imaging containing melanin nanoparticles having a uniform shape and size, thereby providing good dispersibility in water, no cell toxicity, and a long retention time in vivo.
Inventor(s):	Lee; Jin Kyu (Seoul, KR), Ju; Kuk Youn (Seoul, KR), Lee; Jung Hee (Seoul, KR)
Assignee:	Melanis Co., Ltd. (Seoul, KR)
Application Number:	14/391,217
Patent Claims:	1. A contrast agent for nuclear magnetic resonance imaging, comprising: melanin nanoparticles having stable dispersibility in water; and paramagnetic metal ions which are coordinated on the surface of the melanin nanoparticles. 2. The contrast agent according to claim 1, wherein the melanin is obtained from the ink of cuttlefish and has a diameter of 30 nm to 600 nm. 3. The contrast agent according to claim 1, wherein the melanin nanoparticle is synthesized from a melanin precursor of dopamine, DOPA or cysteine, and has a diameter of 30 nm to 600 nm. 4. The contrast agent according to claim 1, wherein the paramagnetic metal ion is one or more metal ions selected from the group consisting of gadolinium (Gd), iron (Fe), manganese (Mn), nickel (Ni), copper (Cu), erbium (Er), europium (Eu), holmium (Ho) and chromium (Cr). 5. The contrast agent according to claim 1, wherein the surface of the melanin nanoparticles is modified with 3-mercaptopropionic acid. 6. The contrast agent according to claim 1, wherein an antibody is bound to the surface of the melanin nanoparticles. 7. The contrast agent according to claim 6, wherein the antibody is Cetuximab or Trastuzumab. 8. The contrast agent of claim 1, further comprising polyethyleneglycol (PEG) attached to the surface of the melanin nanoparticles for surface modification. 9. The contrast agent according to claim 8, wherein the surface of the melanin nanoparticles is modified with amine- or thiol- functionalized PEG. 10. The contrast agent according to claim 8, wherein the PEG has a molecular weight of 1 KDa to 40 KDa. 11. The contrast agent according to claim 8, wherein the surface of the melanin nanoparticles is modified with 3-mercaptopropionic acid. 12. The contrast agent according to claim 8, wherein an antibody is bound to the surface of the melanin nanoparticles. 13. A method for preparing a contrast agent for nuclear magnetic resonance imaging comprising melanin nanoparticles having stable dispersibility in water and paramagnetic metal ions which are coordinated on the surface of the melanin nanoparticles, the method comprising: adding a solution containing paramagnetic metal ions to a solution containing melanin nanoparticles to form coordinate bonds between the paramagnetic metal ions and melanin of the melanin nanoparticles, and forming melanin nanoparticles having stable dispersibility in water. 14. The method according to claim 13, further comprising adding 3-mercaptopropionic acid. 15. The method according to claim 14, further comprising binding the prepared melanin nanoparticles with an antibody. 16. The method according to claim 15, wherein the antibody is Cetuximab or Trastuzumab. 17. The method according to claim 13, wherein the melanin is obtained from the ink of cuttlefish and has a diameter of 30 nm to 600 nm. 18. The method according to claim 13, wherein the melanin nanoparticles are synthesized from a melanin precursor of dopamine, DOPA or cysteine, and have a diameter of 30 nm to 600 nm. 19. The method according to claim 13, wherein the paramagnetic metal ion is one or more metal ions selected from the group consisting of gadolinium (Gd), iron(Fe), manganese (Mn), nickel (Ni), copper (Cu), erbium (Er), europium (Eu), holmium (Ho) and chromium (Cr). 20. The method of claim 13, further comprising adding polyethyleneglycol (PEG) to the solution containing paramagnetic metal ions and melanin nanoparticles. 21. The method according to claim 20, wherein the PEG has a molecular weight of 1 KDa to 40 KDa. 22. The method according to claim 20, wherein the melanin nanoparticles are synthesized from a melanin precursor of dopamine, DOPA or cysteine, and have a diameter of 30 nm to 600 nm. 23. The method according to claim 20, wherein the paramagnetic metal ion is one or more metal ions selected from the group consisting of gadolinium (Gd), iron(Fe), manganese (Mn), nickel (Ni), copper (Cu), erbium (Er), europium (Eu), holmium (Ho) and chromium (Cr). 24. A contrast agent produced by the method of claim 13. 25. A contrast agent produced by the method of claim 20. 26. The contrast agent according to claim 25, wherein the melanin is obtained from the ink of cuttlefish and has a diameter of 30 nm to 600 nm. 27. The contrast agent according to claim 25, wherein the melanin nanoparticles are synthesized from a melanin precursor of dopamine, DOPA or cysteine, and have a diameter of 30 nm to 600 nm. 28. The contrast agent according to claim 25, wherein the paramagnetic metal ion is one or more metal ions selected from the group consisting of gadolinium (Gd), iron (Fe), manganese (Mn), nickel (Ni), copper (Cu), erbium (Er), europium (Eu), holmium (Ho) and chromium (Cr). 29. The contrast agent according to claim 25, wherein the surface of the melanin nanoparticles is modified with amine-or thiol-functionalized PEG. 30. The contrast agent according to claim 25, wherein the PEG has a molecular weight of 1 KDa to 40 KDa. 31. The contrast agent according to claim 25, wherein the surface of the melanin nanoparticles is modified with 3-mercaptopropionic acid. 32. The contrast agent according to claim 25, wherein an antibody is bound to the surface of the melanin nanoparticles. 33. The contrast agent according to claim 32, wherein the antibody is Cetuximab or Trastuzumab.

Details for Patent 9,808,540

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2032-04-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2032-04-09
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2032-04-09
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2032-04-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.